"anti-NMDA receptor encephalitis"[MeSH Terms]

"NMDA receptor encephalitis" AND treatment

PMID: 40426689

PMID: 39893022

anti-NMDA receptor encephalitis 2024 2025 treatment update guidelines rituximab

PMID: 37918394

ls -la /home/daytona/workspace/ 2>/dev/null || mkdir -p /home/daytona/workspace

mkdir -p /home/daytona/workspace/nmda-encephalitis && python3 -c "from reportlab…

~/nmda-encephalitis/generate_pdf.py

from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.lib import colors
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    HRFlowable, KeepTogether, PageBreak
)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY

OUTPUT = "/home/daytona/workspace/nmda-encephalitis/NMDA_Receptor_Encephalitis.pdf"

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    leftMargin=2.2*cm,
    rightMargin=2.2*cm,
    topMargin=2.5*cm,
    bottomMargin=2.5*cm,
    title="Anti-NMDA Receptor Encephalitis",
    author="Orris Medical Reference",
)

styles = getSampleStyleSheet()

# --- Custom Styles ---
title_style = ParagraphStyle(
    "CustomTitle",
    parent=styles["Title"],
    fontSize=22,
    textColor=colors.HexColor("#1a3a5c"),
    spaceAfter=6,
    leading=28,
    alignment=TA_CENTER,
)
subtitle_style = ParagraphStyle(
    "Subtitle",
    parent=styles["Normal"],
    fontSize=11,
    textColor=colors.HexColor("#4a6fa5"),
    spaceAfter=4,
    alignment=TA_CENTER,
)
h1_style = ParagraphStyle(
    "H1",
    parent=styles["Heading1"],
    fontSize=15,
    textColor=colors.white,
    backColor=colors.HexColor("#1a3a5c"),
    spaceBefore=16,
    spaceAfter=8,
    leading=20,
    leftIndent=-0.2*cm,
    rightIndent=-0.2*cm,
    borderPadding=(5, 8, 5, 8),
)
h2_style = ParagraphStyle(
    "H2",
    parent=styles["Heading2"],
    fontSize=12,
    textColor=colors.HexColor("#1a3a5c"),
    spaceBefore=10,
    spaceAfter=4,
    leading=16,
    borderPadding=(2, 0, 2, 0),
)
h3_style = ParagraphStyle(
    "H3",
    parent=styles["Heading3"],
    fontSize=11,
    textColor=colors.HexColor("#4a6fa5"),
    spaceBefore=8,
    spaceAfter=3,
    leading=14,
    fontName="Helvetica-BoldOblique",
)
body_style = ParagraphStyle(
    "Body",
    parent=styles["Normal"],
    fontSize=10,
    leading=15,
    spaceAfter=6,
    alignment=TA_JUSTIFY,
    textColor=colors.HexColor("#222222"),
)
bullet_style = ParagraphStyle(
    "Bullet",
    parent=body_style,
    leftIndent=14,
    bulletIndent=4,
    spaceAfter=3,
    leading=14,
)
sub_bullet_style = ParagraphStyle(
    "SubBullet",
    parent=body_style,
    leftIndent=28,
    bulletIndent=18,
    spaceAfter=2,
    leading=13,
    fontSize=9.5,
)
note_style = ParagraphStyle(
    "Note",
    parent=body_style,
    fontSize=9,
    textColor=colors.HexColor("#555555"),
    leftIndent=10,
    rightIndent=10,
    backColor=colors.HexColor("#f4f7fb"),
    borderPadding=(6, 8, 6, 8),
    borderColor=colors.HexColor("#4a6fa5"),
    borderWidth=0,
    leading=13,
)
ref_style = ParagraphStyle(
    "Ref",
    parent=body_style,
    fontSize=8.5,
    textColor=colors.HexColor("#444444"),
    leading=12,
    spaceAfter=3,
)

def H1(text):
    return Paragraph(f"  {text}", h1_style)

def H2(text):
    return Paragraph(text, h2_style)

def H3(text):
    return Paragraph(text, h3_style)

def B(text):
    return Paragraph(text, body_style)

def BU(text):
    return Paragraph(f"•   {text}", bullet_style)

def SBU(text):
    return Paragraph(f"–   {text}", sub_bullet_style)

def NOTE(text):
    return Paragraph(f"<i>{text}</i>", note_style)

def HR():
    return HRFlowable(width="100%", thickness=0.8, color=colors.HexColor("#c0cfe0"), spaceAfter=4, spaceBefore=4)

def SP(h=6):
    return Spacer(1, h)

def table_style_base():
    return TableStyle([
        ("BACKGROUND", (0, 0), (-1, 0), colors.HexColor("#1a3a5c")),
        ("TEXTCOLOR", (0, 0), (-1, 0), colors.white),
        ("FONTNAME", (0, 0), (-1, 0), "Helvetica-Bold"),
        ("FONTSIZE", (0, 0), (-1, 0), 9),
        ("ALIGN", (0, 0), (-1, 0), "CENTER"),
        ("BOTTOMPADDING", (0, 0), (-1, 0), 7),
        ("TOPPADDING", (0, 0), (-1, 0), 7),
        ("BACKGROUND", (0, 1), (-1, -1), colors.HexColor("#f9fbfd")),
        ("ROWBACKGROUNDS", (0, 1), (-1, -1), [colors.HexColor("#f9fbfd"), colors.HexColor("#e8f0f8")]),
        ("FONTSIZE", (0, 1), (-1, -1), 9),
        ("FONTNAME", (0, 1), (-1, -1), "Helvetica"),
        ("ALIGN", (0, 1), (-1, -1), "LEFT"),
        ("VALIGN", (0, 0), (-1, -1), "MIDDLE"),
        ("TOPPADDING", (0, 1), (-1, -1), 5),
        ("BOTTOMPADDING", (0, 1), (-1, -1), 5),
        ("LEFTPADDING", (0, 0), (-1, -1), 8),
        ("RIGHTPADDING", (0, 0), (-1, -1), 8),
        ("GRID", (0, 0), (-1, -1), 0.5, colors.HexColor("#b0c4de")),
        ("ROUNDEDCORNERS", [4, 4, 4, 4]),
    ])

# ============================================================
# CONTENT
# ============================================================
story = []

# ---- Cover Block ----
story.append(SP(20))
story.append(Paragraph("Anti-NMDA Receptor Encephalitis", title_style))
story.append(Paragraph("(NMDAR-E)", subtitle_style))
story.append(SP(6))
story.append(Paragraph("Etiology · Mechanisms · Pathophysiology · Clinical Features · Treatment · Recent Updates", subtitle_style))
story.append(SP(4))
story.append(Paragraph("Sources: Adams & Victor's Neurology · Bradley & Daroff's · Harrison's 22nd Ed. · Kaplan & Sadock's · PubMed 2023–2025", subtitle_style))
story.append(HR())
story.append(SP(10))

# ============================================================
# 1. OVERVIEW
# ============================================================
story.append(H1("1.  Overview & Definition"))
story.append(B(
    "Anti-NMDA receptor encephalitis (NMDAR-E) is an <b>autoimmune inflammatory disorder of the brain</b> "
    "caused by IgG autoantibodies directed against the <b>GluN1 (NR1) subunit</b> of the N-methyl-D-aspartate "
    "receptor (NMDAR). It was first described by Dalmau et al. in 2007 in young women with ovarian teratoma, "
    "and is now recognized as the <b>most common form of autoimmune encephalitis</b>, surpassing many viral "
    "etiologies in young adults."
))
story.append(B(
    "The condition is notable because: (1) it is potentially fully reversible with prompt treatment, (2) it "
    "mimics primary psychiatric illness early in its course, and (3) the underlying pathogenic mechanism "
    "involves receptor internalization rather than direct cytotoxicity."
))
story.append(SP(4))

# ============================================================
# 2. ETIOLOGY
# ============================================================
story.append(H1("2.  Etiology"))

story.append(H2("2.1  Epidemiology"))
story.append(B(
    "NMDAR-E predominantly affects <b>young women</b> (approximately 80% female), typically in their teens "
    "and twenties, but documented cases span all ages from infants to elderly adults. Incidence has markedly "
    "risen in recent years — attributable to improved diagnostics (expanded antibody panels) rather than a "
    "true increase in prevalence. It is now thought to account for more cases of encephalitis than any single "
    "infectious etiology in patients under 30."
))

story.append(H2("2.2  Tumor-Associated (Paraneoplastic) Etiology"))
story.append(B(
    "In most female patients, the immune response is triggered by neural tissue within a tumor that "
    "aberrantly expresses NMDA receptors, prompting B-cell-mediated antibody production:"
))
story.append(BU("<b>Ovarian teratoma:</b> Most common trigger; found in up to 50% of females under 45 years of age. "
    "The teratoma contains ectopic neural tissue expressing GluN1 antigen."))
story.append(BU("<b>Mediastinal teratoma:</b> Rare alternative location."))
story.append(BU("<b>Small cell lung cancer:</b> Reported in men and older women."))
story.append(BU("<b>Other tumors:</b> Breast cancer, thymoma, neuroblastoma (in children)."))
story.append(SP(4))

story.append(H2("2.3  Non-Paraneoplastic Etiology"))
story.append(B(
    "Approximately <b>40% of all patients have no detectable tumor</b>, representing a purely autoimmune "
    "form. Recognized non-paraneoplastic triggers include:"
))
story.append(BU("<b>Post-infectious NMDAR-E:</b> HSV encephalitis is the best-documented trigger — "
    "NMDAR-E occurs in ~20–30% of patients as a post-HSV immune phenomenon, often presenting weeks "
    "after apparent recovery from the viral illness."))
story.append(BU("<b>Other viral encephalitides:</b> EBV, CMV, and other herpesviruses reported."))
story.append(BU("<b>Idiopathic:</b> No trigger identified; spontaneous autoimmunity presumed."))
story.append(SP(4))
NOTE_TEXT = (
    "Clinical note: In young women with new-onset psychiatric symptoms, a pelvic ultrasound should be "
    "performed as part of the diagnostic workup. Vaginal ultrasound may be necessary when abdominal imaging "
    "misses small ovarian teratomas. For complete tumor exclusion, CT of chest/abdomen/pelvis or "
    "whole-body FDG-PET/CT is warranted."
)
story.append(NOTE(NOTE_TEXT))
story.append(SP(6))

# ============================================================
# 3. MECHANISM
# ============================================================
story.append(H1("3.  Molecular Mechanisms"))

story.append(H2("3.1  The NMDA Receptor — Structure and Function"))
story.append(B(
    "NMDA receptors are <b>ligand-gated ion channels</b> permeable to Ca²⁺, Na⁺, and K⁺, assembled as "
    "tetramers composed of two obligatory GluN1 (NR1) subunits and two GluN2 (NR2) or GluN3 subunits. "
    "They require three concurrent conditions for activation:"
))
story.append(BU("Binding of glutamate (at GluN2 subunit)"))
story.append(BU("Binding of a co-agonist — glycine or D-serine (at GluN1 subunit)"))
story.append(BU("Postsynaptic membrane depolarization to relieve voltage-dependent Mg²⁺ channel block"))
story.append(B(
    "NMDARs are concentrated in the hippocampus and cortex and are essential for synaptic plasticity, "
    "long-term potentiation (LTP), memory encoding, and regulation of oscillatory neural networks."
))

story.append(H2("3.2  Antibody-Mediated Receptor Internalization"))
story.append(B(
    "Anti-GluN1 IgG antibodies do <b>not</b> block the receptor channel directly. Instead, they cause "
    "<b>crosslinking and receptor internalization</b> via endocytosis, leading to a reversible reduction "
    "in surface NMDAR density. This is a critical distinction from direct channel antagonism:"
))
story.append(BU("Antibody crosslinks adjacent receptors → receptor clustering → clathrin-mediated endocytosis"))
story.append(BU("Surface NMDAR expression is reduced by 50–70% in affected neurons"))
story.append(BU("This process is reversible — antibody removal leads to receptor re-expression"))
story.append(BU("No direct neuronal cytotoxicity occurs (unlike anti-Hu/Yo antibodies against intracellular antigens)"))

story.append(H2("3.3  GABAergic Interneuron Disinhibition — The Core Pathophysiological Circuit"))
story.append(B(
    "The clinical syndrome can be explained by preferential loss of NMDAR function on inhibitory "
    "<b>GABAergic interneurons</b> in the cortex and hippocampus:"
))

steps = [
    ("Step 1", "NMDARs on GABAergic interneurons are particularly sensitive to antibody-mediated down-regulation due to their high surface density"),
    ("Step 2", "Loss of excitatory drive on GABAergic interneurons → reduced GABA release → loss of inhibitory tone"),
    ("Step 3", "Glutamatergic pyramidal neurons are disinhibited → net cortical hyperexcitability despite overall NMDAR hypofunction"),
    ("Step 4", "Excessive presynaptic glutamate release further impairs remaining NMDARs in a feedback loop"),
    ("Step 5", "Disruption of corticostriatal and corticolimbic circuits → psychiatric symptoms, dyskinesias, and autonomic dysfunction"),
]
t_data = [["Step", "Mechanism"]] + [[s[0], s[1]] for s in steps]
t = Table(t_data, colWidths=[2.5*cm, 13.5*cm])
t.setStyle(table_style_base())
story.append(t)
story.append(SP(6))

story.append(B(
    "This disinhibition model elegantly explains why the NMDAR-E syndrome closely resembles intoxication "
    "with NMDAR antagonists such as phencyclidine (PCP) or ketamine — both of which produce psychosis, "
    "dissociation, dyskinesias, and autonomic instability at sub-anesthetic doses."
))

story.append(H2("3.4  Complement and T-Cell Contributions"))
story.append(B(
    "Beyond the antibody-receptor interaction, emerging data (2024–2025) highlight additional mechanisms:"
))
story.append(BU("Intrathecal B-cell proliferation and local IgG synthesis within the CNS contributes to the CSF antibody pool"))
story.append(BU("CD4+ T helper cells promote B-cell differentiation and antibody class-switching to IgG"))
story.append(BU("Skull bone marrow and meningeal lymphatic channels are now recognized as CNS immune surveillance routes (Li et al., 2025)"))
story.append(BU("Complement-independent synaptic damage via excessive glutamate-mediated signaling"))
story.append(SP(6))

# ============================================================
# 4. PATHOPHYSIOLOGY
# ============================================================
story.append(H1("4.  Pathophysiology"))

story.append(H2("4.1  Hippocampal and Limbic System Involvement"))
story.append(B(
    "The hippocampus — rich in NMDARs and GABAergic interneurons — is the primary affected region. "
    "NMDAR hypofunction in hippocampal CA1 and CA3 fields disrupts:"
))
story.append(BU("Episodic memory encoding (explains prominent anterograde amnesia)"))
story.append(BU("Spatial and contextual processing"))
story.append(BU("Synchronization of hippocampal-cortical oscillatory networks (theta and gamma rhythms)"))

story.append(H2("4.2  Striatal and Basal Ganglia Involvement"))
story.append(B(
    "NMDAR hypofunction in the striatum disrupts dopaminergic regulation, leading to:"
))
story.append(BU("Orofacial and limb dyskinesias (stereotyped, semi-purposeful movements)"))
story.append(BU("Choreoathetosis — involuntary writhing/flinging movements"))
story.append(BU("Dystonia — sustained abnormal postures"))
story.append(BU("Catatonic features — waxy flexibility, mutism, posturing"))

story.append(H2("4.3  Autonomic Nervous System Dysregulation"))
story.append(B(
    "NMDAR hypofunction in hypothalamic and brainstem autonomic circuits produces:"
))
story.append(BU("Tachycardia, hypertension, diaphoresis — episodes of sympathetic hyperactivation"))
story.append(BU("Hypersalivation, pupillary abnormalities — parasympathetic features"))
story.append(BU("Central hypoventilation — requires mechanical ventilation in severe cases"))
story.append(BU("Hyperthermia — central temperature dysregulation"))

story.append(H2("4.4  Cortical Hyperexcitability and Seizures"))
story.append(B(
    "The GABAergic disinhibition mechanism at the cortical level produces a paradoxical hyperexcitable "
    "state, manifesting as:"
))
story.append(BU("Focal and generalized tonic-clonic seizures"))
story.append(BU("Non-convulsive status epilepticus (frequently unrecognized without EEG)"))
story.append(BU("Pathognomonic EEG pattern: <b>extreme delta brush</b> — delta activity with superimposed "
    "beta frequency bursts, highly specific for severe NMDAR-E"))
story.append(SP(4))

story.append(H2("4.5  Neuroimaging Correlates"))

img_data = [
    ["Modality", "Typical Finding", "Clinical Significance"],
    ["MRI (FLAIR/T2)", "Hyperintensity in medial temporal lobes, hippocampus (30–40% of cases)", "Limbic encephalitis pattern; often normal early"],
    ["FDG-PET (early)", "Mesiotemporal and striatal hypermetabolism", "Reflects inflammatory activation; useful when MRI negative"],
    ["FDG-PET (late)", "Mesiotemporal hypometabolism", "Postinflammatory damage; portends worse prognosis"],
    ["MRI DWI", "Restricted diffusion in cortex (rare)", "Suggests more severe disease"],
    ["EEG", "Generalized slowing, epileptiform discharges, extreme delta brush", "Extreme delta brush highly specific for NMDAR-E"],
]
t2 = Table(img_data, colWidths=[3.5*cm, 7*cm, 5.5*cm])
t2.setStyle(table_style_base())
story.append(t2)
story.append(SP(8))

# ============================================================
# 5. CLINICAL FEATURES
# ============================================================
story.append(H1("5.  Clinical Features"))

story.append(H2("5.1  The Classic Multistage Progression"))
story.append(B(
    "NMDAR-E classically evolves through overlapping clinical stages over days to weeks. Recognition of "
    "the full syndrome is critical — early stages are frequently misdiagnosed as primary psychiatric illness."
))
story.append(SP(4))

stage_data = [
    ["Stage", "Timing", "Dominant Features"],
    ["1 — Prodrome", "Days 1–5", "Low-grade fever, headache, malaise, fatigue, excessive sleepiness. Non-specific; mimics viral illness."],
    ["2 — Psychiatric Phase", "Days 5–20", "Acute-onset psychosis (hallucinations, delusions), agitation, mood lability, behavioral disorganization, echolalia, memory loss. Often leads to psychiatric admission."],
    ["3 — Neurological Phase", "Weeks 2–4", "Seizures (focal or generalized), orofacial dyskinesias, choreoathetosis, catatonia, decreasing consciousness, autonomic instability, central hypoventilation."],
    ["4 — Unresponsive Phase", "Weeks 4–8", "Coma, minimal responsiveness, continued autonomic storms, ICU admission, mechanical ventilation."],
    ["5 — Recovery Phase", "Weeks–months", "Gradual reversal in roughly reverse order of symptom onset. Cognitive deficits, behavioral changes may persist months."],
]
t3 = Table(stage_data, colWidths=[3*cm, 3*cm, 10*cm])
t3.setStyle(table_style_base())
story.append(t3)
story.append(SP(6))

story.append(H2("5.2  Psychiatric Features (Detailed)"))
story.append(BU("<b>Auditory and visual hallucinations</b> — often vivid, complex"))
story.append(BU("<b>Paranoid delusions</b> — persecutory or referential"))
story.append(BU("<b>Severe agitation</b> — may require physical restraint"))
story.append(BU("<b>Mood lability</b> — euphoria, crying, aggression in rapid succession"))
story.append(BU("<b>Echolalia and echopraxia</b>"))
story.append(BU("<b>Mutism</b> — often mistaken for catatonic schizophrenia"))
story.append(BU("<b>Cognitive impairment</b> — working memory failure, disorientation"))
story.append(SP(4))
story.append(NOTE(
    "Important: Psychiatrists are frequently the first specialists to see these patients. "
    "Red flags that should prompt workup for autoimmune encephalitis include: rapid symptom progression "
    "(<3 months), prominent neurological co-symptoms (seizures, movement abnormalities), age <35, "
    "poor or atypical response to antipsychotics, and fever."
))
story.append(SP(4))

story.append(H2("5.3  Neurological Features (Detailed)"))
story.append(H3("Movement Disorders:"))
story.append(BU("<b>Orofacial dyskinesias:</b> Lip smacking, tongue protrusion, chewing movements — highly characteristic"))
story.append(BU("<b>Limb dyskinesias:</b> Choreoathetoid movements of arms and legs"))
story.append(BU("<b>Dystonia:</b> Fixed abnormal posturing"))
story.append(BU("<b>Catatonia:</b> Waxy flexibility, posturing, negativism — overlap with psychiatric presentation"))
story.append(H3("Seizures:"))
story.append(BU("Occur in >75% of patients at some point in the illness"))
story.append(BU("May be focal (temporal lobe semiology) or generalized tonic-clonic"))
story.append(BU("Non-convulsive status epilepticus is common and often missed clinically"))
story.append(BU("Seizures may precede psychiatric symptoms or emerge later"))
story.append(H3("Autonomic Instability:"))
story.append(BU("Hypertension and hypotension (labile)"))
story.append(BU("Tachycardia, bradycardia"))
story.append(BU("Diaphoresis, hypersalivation, hyperthermia"))
story.append(BU("Pupillary dilatation or other pupillary abnormalities"))
story.append(BU("<b>Central hypoventilation</b> — most feared complication, requiring mechanical ventilation in ~70% of hospitalized patients"))
story.append(SP(4))

story.append(H2("5.4  Clinical Features by Population"))
feat_data = [
    ["Population", "Notable Differences"],
    ["Young women (most typical)", "Full multistage syndrome; ovarian teratoma in ~50%; best prognosis with tumor removal"],
    ["Children (<12 years)", "Movement disorders and behavioral changes often predominate over psychosis; seizures more prominent; good long-term outcomes reported (Chen et al., 2024)"],
    ["Males", "No teratoma; less common but full syndrome possible; often younger children or older adults"],
    ["Elderly", "Atypical presentations; cognitive decline may dominate; lower tumor association"],
    ["Post-HSV NMDAR-E", "Emerges 2–6 weeks after apparent HSV recovery; movement disorders prominent; may lack tumor"],
]
t4 = Table(feat_data, colWidths=[5*cm, 11*cm])
t4.setStyle(table_style_base())
story.append(t4)
story.append(SP(8))

# ============================================================
# 6. DIAGNOSIS
# ============================================================
story.append(H1("6.  Diagnosis"))

story.append(H2("6.1  Diagnostic Criteria (Graus et al., 2016)"))
story.append(B(
    "The diagnosis requires ONE or more of the following six symptom groups, with acute/subacute onset "
    "(<3 months), AND confirmation by anti-GluN1 IgG antibodies in CSF:"
))
criteria = [
    "Abnormal (psychiatric) behavior or cognitive dysfunction",
    "Speech dysfunction (pressured speech, verbal reduction, mutism)",
    "Seizures",
    "Movement disorder, dyskinesias, or rigidity/abnormal postures",
    "Decreased level of consciousness",
    "Autonomic dysfunction or central hypoventilation",
]
for i, c in enumerate(criteria, 1):
    story.append(BU(f"<b>Group {i}:</b> {c}"))
story.append(SP(4))

story.append(H2("6.2  Laboratory and Investigations"))
diag_data = [
    ["Investigation", "Finding", "Notes"],
    ["CSF anti-GluN1 IgG", "Positive (gold standard)", "More specific than serum; can be positive when serum negative"],
    ["Serum anti-GluN1 IgG", "Positive (sensitive screen)", "Positive in ~85%; test both serum AND CSF"],
    ["CSF routine analysis", "Lymphocytic pleocytosis (>80%), elevated protein, oligoclonal bands", "WBC typically 10–200 cells/μL; protein mildly elevated"],
    ["EEG", "Generalized slowing, epileptiform discharges, extreme delta brush pattern", "Extreme delta brush highly specific; always perform continuous EEG in severe cases"],
    ["MRI brain (FLAIR/T2)", "Mesiotemporal hyperintensity (~30–40%); often normal", "Normal MRI does not exclude diagnosis"],
    ["FDG-PET brain", "Mesiotemporal/striatal hypermetabolism (early); hypometabolism (late)", "Useful when MRI negative; reflects inflammatory activity"],
    ["Pelvic ultrasound", "Ovarian teratoma", "First-line for females; vaginal ultrasound more sensitive for small lesions"],
    ["CT chest/abdomen/pelvis", "Tumor screening", "Indicated when pelvic US negative"],
    ["Whole-body FDG-PET/CT", "Occult tumor detection", "Best sensitivity for occult malignancy"],
]
t5 = Table(diag_data, colWidths=[4.5*cm, 6*cm, 5.5*cm])
t5.setStyle(table_style_base())
story.append(t5)
story.append(SP(6))

story.append(H2("6.3  Differential Diagnosis"))
story.append(B("NMDAR-E must be distinguished from:"))
diff_data = [
    ["Condition", "Key Differentiating Features"],
    ["Viral encephalitis (HSV)", "Fever more prominent; CSF pleocytosis with high protein; MRI temporal lobe signal; PCR positive"],
    ["First-episode schizophrenia", "No fever, seizures, or autonomic instability; chronic onset; no CSF changes; older age at onset"],
    ["Bipolar disorder with psychosis", "Prior episodes; no neurological signs; normal EEG and CSF"],
    ["Neuroleptic malignant syndrome", "History of antipsychotic exposure; hyperthermia, rigidity, elevated CK"],
    ["Viral/toxic encephalopathy", "Toxicology screen; clinical context; no autoantibodies"],
    ["Other autoimmune encephalitis", "LGI1: faciobrachial dystonic seizures, hyponatremia; GABA-B: prominent early seizures; AMPA-R: memory-predominant"],
    ["Metabolic encephalopathy", "Electrolytes, glucose, ammonia; acute onset; resolves with correction"],
]
t6 = Table(diff_data, colWidths=[5*cm, 11*cm])
t6.setStyle(table_style_base())
story.append(t6)
story.append(SP(8))

# ============================================================
# 7. TREATMENT
# ============================================================
story.append(H1("7.  Treatment"))

story.append(H2("7.1  Guiding Principles"))
story.append(BU("<b>Time is brain:</b> Earlier treatment initiation is the single most important prognostic factor"))
story.append(BU("<b>Dual approach:</b> Remove the immunogenic trigger (tumor) AND suppress the immune response"))
story.append(BU("Do not wait for antibody confirmation if clinical suspicion is high — begin treatment empirically"))
story.append(BU("Monitor for relapses: occur in ~12–25% of patients, more common without second-line therapy"))
story.append(SP(4))

story.append(H2("7.2  First-Line Immunotherapy"))
fl_data = [
    ["Treatment", "Regimen", "Mechanism", "Notes"],
    ["Tumor removal\n(Oophorectomy)", "Expedited surgery once teratoma confirmed", "Removes immunogenic stimulus; most effective single intervention", "Subsidence of antibody titers over weeks post-removal; dramatic improvement in many"],
    ["High-dose IV Methylprednisolone", "1 g/day IV × 5 days", "Anti-inflammatory; suppresses B and T cell activity", "Start concurrently with IVIG or PLEX"],
    ["IV Immunoglobulin (IVIG)", "0.4 g/kg/day × 5 days", "Antibody neutralization, Fc receptor blockade, immune modulation", "Can use alone or with PLEX; roughly equivalent efficacy to PLEX"],
    ["Plasma Exchange (PLEX)", "5–7 exchanges over 10–14 days", "Directly removes circulating autoantibodies", "Preferred in rapidly deteriorating patients; logistics limit use in ICU"],
]
t7 = Table(fl_data, colWidths=[3.5*cm, 3.5*cm, 5*cm, 4*cm])
t7.setStyle(table_style_base())
story.append(t7)
story.append(SP(6))

story.append(H2("7.3  Second-Line Immunotherapy"))
story.append(B(
    "Approximately <b>25% of patients fail first-line therapy</b> and require second-line agents, typically "
    "initiated 2–4 weeks after first-line if no significant improvement:"
))
sl_data = [
    ["Agent", "Mechanism", "Typical Use"],
    ["Rituximab", "Anti-CD20 monoclonal antibody; B-cell depletion", "Most evidence-based second-line agent; 375 mg/m² IV weekly × 4 doses, or 1000 mg × 2 doses"],
    ["Cyclophosphamide", "Alkylating agent; broad lymphocyte suppression", "Often combined with rituximab for severe cases; 750 mg/m² IV monthly"],
    ["Mycophenolate mofetil", "Inhibits purine synthesis in lymphocytes", "Maintenance immunosuppression after acute phase; 1–3 g/day orally"],
    ["Azathioprine", "Purine analog; inhibits lymphocyte proliferation", "Alternative maintenance agent"],
    ["Bortezomib", "Proteasome inhibitor; targets plasma cells", "Used in highly refractory cases to eliminate antibody-secreting plasma cells"],
    ["Intrathecal rituximab", "Direct CNS B-cell depletion", "Emerging 2024: case series show rapid recovery in IV rituximab-refractory patients"],
]
t8 = Table(sl_data, colWidths=[4*cm, 6*cm, 6*cm])
t8.setStyle(table_style_base())
story.append(t8)
story.append(SP(6))

story.append(H2("7.4  Symptomatic and Supportive Management"))
story.append(BU("<b>Seizure management:</b> Levetiracetam preferred (fewer drug interactions); benzodiazepines for acute seizures; valproate as alternative"))
story.append(BU("<b>ICU care:</b> Mechanical ventilation for hypoventilation; hemodynamic monitoring for autonomic instability"))
story.append(BU("<b>Agitation:</b> Low-dose benzodiazepines preferred; antipsychotics used cautiously (may worsen dyskinesias and lower seizure threshold)"))
story.append(BU("<b>Catatonia:</b> Benzodiazepines (lorazepam) first; ECT reported in refractory catatonia"))
story.append(BU("<b>Nutrition:</b> NG/PEG tube feeding during prolonged impaired consciousness"))
story.append(BU("<b>DVT prophylaxis:</b> Pharmacological ± mechanical during immobility"))
story.append(BU("<b>Psychiatric follow-up:</b> Cognitive rehabilitation, neuropsychological testing at recovery"))
story.append(SP(4))

story.append(H2("7.5  Fertility Considerations"))
story.append(B(
    "Oophorectomy decisions are difficult in young women given the impact on fertility. "
    "Bilateral oophorectomy is rarely needed. Unilateral removal of the affected ovary is standard. "
    "In women of childbearing age with a small teratoma and good immune response to initial therapy, "
    "a shared decision-making approach is appropriate regarding surgical timing. "
    "Immune treatment should be started while awaiting surgery in highly symptomatic patients "
    "(Adams and Victor's Principles of Neurology, 12th Ed.)."
))
story.append(SP(6))

story.append(H2("7.6  Treatment Algorithm"))
alg_data = [
    ["Step", "Action", "Timeframe"],
    ["1", "Clinical suspicion → Immediate serum + CSF anti-GluN1 antibodies, MRI, EEG, pelvic ultrasound", "Day 1"],
    ["2", "Start empiric IV methylprednisolone 1 g/day + IVIG 0.4 g/kg/day (do not wait for antibody result if high suspicion)", "Day 1–2"],
    ["3", "Tumor identified → Expedited surgical removal (oophorectomy)", "Days 3–7"],
    ["4", "Reassess at 2–4 weeks: If improving → continue steroids + supportive care", "Week 2–4"],
    ["5", "No significant improvement → Add rituximab ± cyclophosphamide", "Week 2–6"],
    ["6", "Still refractory → Consider bortezomib, intrathecal rituximab, experimental agents", "Week 4–8+"],
    ["7", "Relapse → Repeat first-line therapy; consider long-term maintenance immunosuppression", "As needed"],
]
t9 = Table(alg_data, colWidths=[1.5*cm, 11*cm, 3.5*cm])
t9.setStyle(table_style_base())
story.append(t9)
story.append(SP(8))

# ============================================================
# 8. PROGNOSIS
# ============================================================
story.append(H1("8.  Prognosis and Outcomes"))
story.append(B(
    "Despite the severity of acute presentation (many patients require ICU and ventilation), "
    "NMDAR-E carries a <b>favorable prognosis</b> with prompt treatment:"
))
prog_data = [
    ["Outcome Metric", "Figures"],
    ["Full or near-full recovery", "~75–80% with appropriate treatment"],
    ["Moderate disability at follow-up", "~15%"],
    ["Severe disability or death", "<5%"],
    ["Relapse rate", "12–25% (higher without second-line therapy or incomplete tumor removal)"],
    ["Time to full recovery", "Weeks to >12 months; median 3–6 months"],
    ["Recovery order", "Reverse of symptom onset: autonomic → consciousness → movement → cognition → behavior"],
    ["Children outcome (Chen et al., 2024)", "Good long-term functional outcomes; early treatment critical"],
]
t10 = Table(prog_data, colWidths=[7*cm, 9*cm])
t10.setStyle(table_style_base())
story.append(t10)
story.append(SP(4))
story.append(NOTE(
    "Prognostic factors favoring recovery: early treatment initiation, tumor removal, younger age, "
    "lower CSF antibody titers at follow-up. Factors associated with worse outcomes: delayed diagnosis, "
    "need for ICU care for >3 months, high relapse frequency."
))
story.append(SP(8))

# ============================================================
# 9. RECENT UPDATES
# ============================================================
story.append(H1("9.  Recent Updates (2023–2025)"))

story.append(H2("9.1  ExTINGUISH Trial — Inebilizumab (2025)"))
story.append(B(
    "A <b>Phase 2B double-blind randomized international trial</b> (NIH-funded) is testing "
    "<b>inebilizumab</b>, an anti-CD19 monoclonal antibody currently approved for neuromyelitis optica "
    "spectrum disorder (NMOSD). Published in <i>Neurology</i> Open Access (2025)."
))
story.append(BU("Unlike rituximab (anti-CD20), inebilizumab targets CD19+ B cells including <b>plasmablasts and plasma cells</b> — providing broader and more sustained B-cell depletion"))
story.append(BU("Enrolling at dozens of international sites including WashU Medicine"))
story.append(BU("Primary endpoint: safety and efficacy vs. placebo in NMDAR-E"))
story.append(BU("Could become the first formal randomized trial to establish an evidence-based second-line standard"))
story.append(SP(4))

story.append(H2("9.2  CAAR T-Cell Therapy — Precision Autoimmune Targeting (Cell, 2023)"))
story.append(B(
    "Reincke et al. (PMID 37918394, Cell 2023) developed <b>chimeric autoantibody receptor (CAAR) T cells</b> "
    "engineered to selectively eliminate anti-NMDAR B cells — without broad immunosuppression."
))
story.append(BU("NMDAR-CAARs: multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ signaling domains"))
story.append(BU("Recognize a large panel of human patient-derived autoantibodies"))
story.append(BU("Selectively kill anti-NMDAR B cells even in the presence of high autoantibody concentrations"))
story.append(BU("In murine models: sustained reduction in autoantibody levels; no off-target toxicity"))
story.append(BU("Paves the way for <b>Phase I/II clinical trials</b> — the first antigen-specific cellular therapy for autoimmune encephalitis"))
story.append(SP(4))

story.append(H2("9.3  Intrathecal Rituximab for Refractory Cases (2024)"))
story.append(B(
    "A 2024 Frontiers in Immunology case series (Reda et al.) demonstrated <b>rapid recovery</b> after "
    "intrathecal rituximab in patients refractory to both first-line and IV second-line therapy. "
    "This approach delivers rituximab directly to the intrathecal B-cell compartment, bypassing "
    "the blood-brain barrier."
))
story.append(BU("Approximately 25% of NMDAR-E cases are refractory to standard first- and second-line treatments"))
story.append(BU("Intrathecal rituximab may rescue patients who fail systemic rituximab"))
story.append(BU("Evidence base: case reports and small series only; requires formal trials"))
story.append(SP(4))

story.append(H2("9.4  Combination Anti-B-Cell/Anti-Plasma-Cell Therapy (2025)"))
story.append(B(
    "A 2025 Frontiers in Immunology report describes use of <b>ofatumumab (anti-CD20) combined with "
    "daratumumab (anti-CD38)</b> in severe refractory NMDAR-E. Rituximab resistance may arise because "
    "long-lived plasma cells that survive rituximab continue producing autoantibodies. Daratumumab "
    "targets CD38+ plasma cells, potentially addressing this resistance mechanism."
))
story.append(SP(4))

story.append(H2("9.5  Updated Meta-Analysis on Treatment (2025)"))
story.append(B(
    "A comprehensive meta-analysis (Joubert et al., Journal of Neuroinflammation, 2025) confirmed:"
))
story.append(BU("No FDA-approved treatments exist for NMDAR-E as of 2025 — all immunotherapy is off-label"))
story.append(BU("Early use of both first- and second-line immunotherapy has increased significantly since 2019"))
story.append(BU("Early second-line therapy (within weeks, not months) is associated with better functional outcomes"))
story.append(BU("Tumor removal remains the most impactful intervention in teratoma-associated cases"))
story.append(SP(4))

story.append(H2("9.6  Pathophysiology Advances — Skull Meningeal Channels (2025)"))
story.append(B(
    "Li et al. (Cell Death & Disease, 2025) demonstrated that <b>skull bone marrow and meningeal lymphatic "
    "channels</b> serve as critical routes for CNS immune surveillance. In NMDAR-E, these channels may "
    "facilitate trafficking of autoreactive B cells and antibodies into the CNS compartment, explaining "
    "the intrathecal IgG synthesis. This opens new therapeutic targets along meningeal lymphatic pathways."
))
story.append(SP(4))

story.append(H2("9.7  Long-Term Outcomes in Children (Neurology, 2024)"))
story.append(B(
    "Chen et al. (Neurology Neuroimmunology & Neuroinflammation, 2024) published data on <b>very long-term "
    "functional outcomes</b> in pediatric NMDAR-E:"
))
story.append(BU("Children have favorable long-term outcomes with early aggressive treatment"))
story.append(BU("Residual cognitive and behavioral deficits persist in a subset, emphasizing importance of neuropsychological follow-up"))
story.append(BU("Relapse rates similar to adults; long-term immunosuppression may be warranted in high-risk cases"))
story.append(SP(8))

# ============================================================
# 10. SUMMARY TABLE
# ============================================================
story.append(H1("10.  Rapid Reference Summary"))
story.append(SP(4))
summary_data = [
    ["Aspect", "Key Points"],
    ["Antibody target", "IgG anti-GluN1 (NR1 subunit of NMDAR)"],
    ["Demographics", "Young women (80%); all ages and sexes possible"],
    ["Most common trigger", "Ovarian teratoma (up to 50% in women <45); no tumor in ~40%"],
    ["Core mechanism", "Antibody-mediated NMDAR internalization → GABAergic interneuron hypofunction → disinhibition → cortical hyperexcitability"],
    ["Clinical stages", "Prodrome → Psychiatric → Neurological → Unresponsive → Recovery"],
    ["Classic triad", "Psychosis + Seizures + Orofacial dyskinesias"],
    ["Autonomic features", "Labile BP, tachycardia, diaphoresis, hyperthermia, central hypoventilation"],
    ["Diagnosis", "CSF + serum anti-GluN1 IgG; CSF pleocytosis; EEG (extreme delta brush); MRI; tumor screen"],
    ["First-line Rx", "Tumor removal + IV methylprednisolone + IVIG/PLEX"],
    ["Second-line Rx", "Rituximab ± cyclophosphamide; mycophenolate mofetil (maintenance)"],
    ["Emerging Rx (2025)", "Inebilizumab (ExTINGUISH trial); CAAR T cells; intrathecal rituximab; ofatumumab + daratumumab"],
    ["Prognosis", "~80% good recovery; relapses in 12–25%; reversible if treated early"],
    ["FDA-approved Rx", "None as of 2025 — all treatment is off-label"],
]
t11 = Table(summary_data, colWidths=[5.5*cm, 10.5*cm])
t11.setStyle(table_style_base())
story.append(t11)
story.append(SP(10))

# ============================================================
# REFERENCES
# ============================================================
story.append(H1("References & Sources"))
story.append(SP(4))

refs = [
    ("Adams and Victor's Principles of Neurology, 12th Edition",
     "Anti-NMDA Encephalitis section, p. 697. McGraw-Hill."),
    ("Bradley and Daroff's Neurology in Clinical Practice",
     "Chapters on Paraneoplastic & Autoimmune Disorders, Limbic Encephalitis (Ch. 98). Elsevier."),
    ("Harrison's Principles of Internal Medicine, 22nd Ed. (2025)",
     "Autoimmune Encephalitis and Other Causes of Dementia. McGraw-Hill Medical."),
    ("Kaplan & Sadock's Comprehensive Textbook of Psychiatry",
     "Autoimmune and Inflammatory Disease; Ion Channels and Neuropsychiatric Disorders. Wolters Kluwer."),
    ("Plum and Posner's Diagnosis and Treatment of Stupor and Coma",
     "Paraneoplastic syndromes and autoantibody-mediated encephalitis. Oxford University Press."),
    ("Dalmau J et al. (2007)",
     "Anti-NMDA-receptor encephalitis: case series and analysis. Lancet Neurology 7:1091, 2008. [Original description]"),
    ("Titulaer MJ et al. (2013)",
     "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurology 12(2):157–165."),
    ("Graus F et al. (2016)",
     "A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology 15(4):391–404. [Consensus diagnostic criteria]"),
    ("Reincke SM et al. (2023)",
     "Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell 186(23):4837–4850. PMID: 37918394."),
    ("Guasp M, Dalmau J (2025)",
     "Autoimmune Encephalitis. Medical Clinics of North America. PMID: 39893022."),
    ("Padureanu V et al. (2025)",
     "Anti-NMDA Receptor Encephalitis: A Narrative Review. Brain Sciences 15(5):518. PMID: 40426689."),
    ("Wong KH, Day GS et al. (2025)",
     "A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial. Neurology Open Access 1(2):e000007."),
    ("Reda M et al. (2024)",
     "Case report: Rapid recovery after intrathecal rituximab administration in refractory anti-NMDA receptor encephalitis. Frontiers in Immunology 15:1369587."),
    ("Chen LW et al. (2024)",
     "Very Long-Term Functional Outcomes and Dependency in Children With Anti-NMDA Receptor Encephalitis. Neurology Neuroimmunology & Neuroinflammation 11(3):e200235."),
    ("Li L et al. (2025)",
     "Skull bone marrow and skull meninges channels: redefining the landscape of CNS immune surveillance. Cell Death & Disease 16:53."),
]

for title, detail in refs:
    story.append(Paragraph(f"<b>{title}.</b> {detail}", ref_style))
    story.append(SP(2))

story.append(SP(10))
story.append(HR())
story.append(Paragraph(
    "Generated by Orris Medical AI · May 2026 · For educational purposes · Sources: Standard medical textbooks and peer-reviewed literature",
    ParagraphStyle("Footer", parent=body_style, fontSize=8, textColor=colors.grey, alignment=TA_CENTER)
))

# Build PDF
doc.build(story)
print(f"PDF created: {OUTPUT}")

cd /home/daytona/workspace/nmda-encephalitis && python3 generate_pdf.py 2>&1

ls -lh /home/daytona/workspace/nmda-encephalitis/NMDA_Receptor_Encephalitis.pdf